Three stocks in the biotech industry that are receiving positive attention as of late are Advaxis, Inc. (NASDAQ:ADXS), Halozyme Therapeutics, Inc. (NASDAQ:HALO), and Nektar Therapeutics (NASDAQ:NKTR).
Halozyme Therapeutics, Inc. (NASDAQ:HALO) closed at last trade at $20.73 a stock. The financial results for the company were released for the second quarter, which ended on June 30. The highlights of this report, unveiled on August 10, include a net income of $3.0 million (which works out to about 0.02 a share) and $43.4 million in revenues. The revenues are up from the same quarter the year previously, when they were at $18.4 million. That change in number can be explained largely by the $23 million payment for a collaboration with AbbVie.
Nektar Therapeutics (NASDAQ:NKTR) closed at $11.00 a share in the last trading session, which was up +3.19%. It was only recently that the company appointed R. Scott Greer to its Board of Directors as an independent director, as well as appointing him to the Board’s Audit Committee. Greer is filling the spot of Timothy Petersen, who resigned.
Advaxis, Inc. (NASDAQ:ADXS) closed at the price of $17.22 a share in the last trading session; it was up +3.86%. The company’s Board of Directors only days before (August 13) had appointed to its Board the Honorable Tom Ridge. He is the first Secretary of the US Department of Homeland Security, as well as the 43rd Governor of Pennsylvania. He has a law degree from Penn State University and is also the CEO of Ridge Global. In the short-term, since August 12, the stock has been on an uptrend, although over the long-term it has been down since August 4 of this year. It’s year’s high was on June 8, when it rose to 30.13, while the year’s low was 6.8, which came on January 22, 2015.